Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC

Study Summary

This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.